{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:15:47Z","timestamp":1794348947918,"version":"4.9.0"},"reference-count":264,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["225263\/Z\/22\/Z"],"award-info":[{"award-number":["225263\/Z\/22\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["225263\/Z\/22\/Z"],"award-info":[{"award-number":["225263\/Z\/22\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002283","name":"Alzheimer's Research UK","doi-asserted-by":"publisher","award":["2021B-001"],"award-info":[{"award-number":["2021B-001"]}],"id":[{"id":"10.13039\/501100002283","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A major challenge in Parkinson\u2019s disease is the variability in symptoms and rates of progression, underpinned by heterogeneity of pathological processes. Biomarkers are urgently needed for accurate diagnosis, patient stratification, monitoring disease progression and precise treatment. These were previously lacking, but recently, novel imaging and fluid biomarkers have been developed. Here, we consider new imaging approaches showing sensitivity to brain tissue composition, and examine novel fluid biomarkers showing specificity for pathological processes, including seed amplification assays and extracellular vesicles. We reflect on these biomarkers in the context of new biological staging systems, and on emerging techniques currently in development.<\/jats:p>","DOI":"10.1038\/s41467-024-49949-9","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T16:02:18Z","timestamp":1720195338000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":133,"title":["Neuroimaging and fluid biomarkers in Parkinson\u2019s disease in an era of targeted interventions"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2808-072X","authenticated-orcid":false,"given":"Angeliki","family":"Zarkali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6107-0326","authenticated-orcid":false,"given":"George E. C.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5092-6325","authenticated-orcid":false,"given":"Rimona S.","family":"Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,5]]},"reference":[{"key":"49949_CR1","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"ER Dorsey","year":"2018","unstructured":"Dorsey, E. R. et al. Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 17, 939\u2013953 (2018).","journal-title":"Lancet Neurol."},{"key":"49949_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1474-4422(16)30291-5","volume":"16","author":"DJ Irwin","year":"2017","unstructured":"Irwin, D. J. et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol. 16, 55\u201365 (2017).","journal-title":"Lancet Neurol."},{"key":"49949_CR3","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1474-4422(21)00061-2","volume":"20","author":"N Vijiaratnam","year":"2021","unstructured":"Vijiaratnam, N., Simuni, T., Bandmann, O., Morris, H. R. & Foltynie, T. Progress towards therapies for disease modification in Parkinson\u2019s disease. Lancet Neurol. 20, 559\u2013572 (2021).","journal-title":"Lancet Neurol."},{"key":"49949_CR4","doi-asserted-by":"publisher","unstructured":"Simuni, T. et al. Biological Definition of Neuronal alpha-Synuclein Disease: Towards an Integrated Staging System for Research https:\/\/doi.org\/10.1016\/S1474-4422(23)00405-2 (2024).","DOI":"10.1016\/S1474-4422(23)00405-2"},{"key":"49949_CR5","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"GU H\u00f6glinger","year":"2024","unstructured":"H\u00f6glinger, G. U. et al. A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 23, 191\u2013204 (2024).","journal-title":"Lancet Neurol."},{"key":"49949_CR6","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/mds.27361","volume":"33","author":"T Simuni","year":"2018","unstructured":"Simuni, T. et al. Longitudinal Change of Clinical and Biological Measures in Early Parkinson\u2019s Disease: Parkinson\u2019s Progression Markers Initiative Cohort. Mov. Disord. J. Mov. Disord. Soc. 33, 771\u2013782 (2018).","journal-title":"Mov. Disord. J. Mov. Disord. Soc."},{"key":"49949_CR7","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1212\/WNL.0000000000002651","volume":"87","author":"B Mollenhauer","year":"2016","unstructured":"Mollenhauer, B. et al. Monitoring of 30 marker candidates in early Parkinson disease as progression markers. Neurology 87, 168\u2013177 (2016).","journal-title":"Neurology"},{"key":"49949_CR8","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1212\/WNL.0000000000004609","volume":"89","author":"B Mollenhauer","year":"2017","unstructured":"Mollenhauer, B. et al. Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. Neurology 89, 1959\u20131969 (2017).","journal-title":"Neurology"},{"key":"49949_CR9","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/mds.26578","volume":"31","author":"S Hall","year":"2016","unstructured":"Hall, S. et al. Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson\u2019s Disease. Mov. Disord. 31, 898\u2013905 (2016).","journal-title":"Mov. Disord."},{"key":"49949_CR10","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1007\/s00330-020-07240-7","volume":"31","author":"SJ Cho","year":"2021","unstructured":"Cho, S. J. et al. Diagnostic performance of neuromelanin-sensitive magnetic resonance imaging for patients with Parkinson\u2019s disease and factor analysis for its heterogeneity: a systematic review and meta-analysis. Eur. Radiol. 31, 1268\u20131280 (2021).","journal-title":"Eur. Radiol."},{"key":"49949_CR11","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/mdc3.13710","volume":"10","author":"A Grossauer","year":"2023","unstructured":"Grossauer, A. et al. \u03b1-Synuclein Seed Amplification Assays in the Diagnosis of Synucleinopathies Using Cerebrospinal Fluid\u2014A Systematic Review and Meta-Analysis. Mov. Disord. Clin. Pract. 10, 737\u2013747 (2023).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"49949_CR12","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1212\/WNL.0000000000001991","volume":"85","author":"S Palmqvist","year":"2015","unstructured":"Palmqvist, S. et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology 85, 1240\u20131249 (2015).","journal-title":"Neurology"},{"key":"49949_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40035-023-00374-w","volume":"12","author":"W Paslawski","year":"2023","unstructured":"Paslawski, W. et al. Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson\u2019s disease. Transl. Neurodegener. 12, 42 (2023).","journal-title":"Transl. Neurodegener."},{"key":"49949_CR14","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1038\/s43587-023-00478-y","volume":"3","author":"JB Pereira","year":"2023","unstructured":"Pereira, J. B. et al. DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease. Nat. Aging 3, 1201\u20131209 (2023).","journal-title":"Nat. Aging"},{"key":"49949_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41122-y","volume":"14","author":"M Del Campo","year":"2023","unstructured":"Del Campo, M. et al. CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer\u00b4s disease. Nat. Commun. 14, 5635 (2023).","journal-title":"Nat. Commun."},{"key":"49949_CR16","doi-asserted-by":"publisher","first-page":"e12385","DOI":"10.1002\/trc2.12385","volume":"9","author":"J Cummings","year":"2023","unstructured":"Cummings, J. et al. Alzheimer\u2019s disease drug development pipeline: 2023. Alzheimers Dement. N. Y. N. 9, e12385 (2023).","journal-title":"Alzheimers Dement. N. Y. N."},{"key":"49949_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in Early Alzheimer\u2019s Disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"49949_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32944-3","volume":"13","author":"Y Jiang","year":"2022","unstructured":"Jiang, Y. et al. Preclinical and randomized clinical evaluation of the p38\u03b1 kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration. Nat. Commun. 13, 5308 (2022).","journal-title":"Nat. Commun."},{"key":"49949_CR19","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/ana.25103","volume":"82","author":"V Kaasinen","year":"2017","unstructured":"Kaasinen, V. & Vahlberg, T. Striatal dopamine in Parkinson disease: A meta-analysis of imaging studies. Ann. Neurol. 82, 873\u2013882 (2017).","journal-title":"Ann. Neurol."},{"key":"49949_CR20","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1001\/archneur.59.4.580","volume":"59","author":"MJ Ribeiro","year":"2002","unstructured":"Ribeiro, M. J. et al. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch. Neurol. 59, 580\u2013586 (2002).","journal-title":"Arch. Neurol."},{"key":"49949_CR21","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/jnc.15561","volume":"164","author":"N Nicastro","year":"2023","unstructured":"Nicastro, N., Nencha, U., Burkhard, P. R. & Garibotto, V. Dopaminergic imaging in degenerative parkinsonisms, an established clinical diagnostic tool. J. neurochemistry 164, 346\u2013363 (2023).","journal-title":"J. neurochemistry"},{"key":"49949_CR22","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1212\/WNL.0b013e318248e520","volume":"78","author":"R de la Fuente-Fern\u00e1ndez","year":"2012","unstructured":"de la Fuente-Fern\u00e1ndez, R. Role of DaTSCAN and clinical diagnosis in Parkinson disease. Neurology 78, 696\u2013701 (2012).","journal-title":"Neurology"},{"key":"49949_CR23","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1093\/brain\/awaa365","volume":"144","author":"D Arnaldi","year":"2021","unstructured":"Arnaldi, D. et al. Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder. Brain: a J. Neurol. 144, 278\u2013287 (2021).","journal-title":"Brain: a J. Neurol."},{"key":"49949_CR24","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1001\/jamaneurol.2017.0985","volume":"74","author":"D Jennings","year":"2017","unstructured":"Jennings, D. et al. Conversion to Parkinson disease in the PARS hyposmic and dopamine transporter-deficit prodromal cohort. JAMA Neurol. 74, 933\u2013940 (2017).","journal-title":"JAMA Neurol."},{"key":"49949_CR25","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/ene.12444","volume":"21","author":"F Brigo","year":"2014","unstructured":"Brigo, F., Matinella, A., Erro, R. & Tinazzi, M. [123I]FP-CIT SPECT (DaTSCAN) may be a useful tool to differentiate between Parkinson\u2019s disease and vascular or drug-induced parkinsonisms: a meta-analysis. Eur. J. Neurol. 21, 1369\u2013e90 (2014).","journal-title":"Eur. J. Neurol."},{"key":"49949_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/biomedicines9010012","volume":"9","author":"C-Y Chien","year":"2020","unstructured":"Chien, C.-Y., Hsu, S.-W., Lee, T.-L., Sung, P.-S. & Lin, C.-C. Using Artificial Neural Network to Discriminate Parkinson\u2019s Disease from Other Parkinsonisms by Focusing on Putamen of Dopamine Transporter SPECT Images. Biomedicines 9, 12 (2020).","journal-title":"Biomedicines"},{"key":"49949_CR27","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1080\/01616412.2017.1312211","volume":"39","author":"L Brajkovic","year":"2017","unstructured":"Brajkovic, L. et al. The utility of FDG-PET in the differential diagnosis of Parkinsonism. Neurological Res. 39, 675\u2013684 (2017).","journal-title":"Neurological Res."},{"key":"49949_CR28","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.2967\/jnumed.116.186403","volume":"58","author":"PT Meyer","year":"2017","unstructured":"Meyer, P. T., Frings, L., Rucker, G. & Hellwig, S. (18)F-FDG PET in Parkinsonism: Differential diagnosis and evaluation of cognitive impairment. J. Nucl. Med.: Off. Publ., Soc. Nucl. Med. 58, 1888\u20131898 (2017).","journal-title":"J. Nucl. Med.: Off. Publ., Soc. Nucl. Med."},{"key":"49949_CR29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/mds.29236","volume":"38","author":"P Mattioli","year":"2023","unstructured":"Mattioli, P. et al. Derivation and validation of a phenoconversion-related pattern in idiopathic rapid eye movement behavior disorder. Mov. Disord.: Off. J. Mov. Disord. Soc. 38, 57\u201367 (2023).","journal-title":"Mov. Disord.: Off. J. Mov. Disord. Soc."},{"key":"49949_CR30","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1007\/s10072-023-06829-2","volume":"44","author":"B Orso","year":"2023","unstructured":"Orso, B. et al. Validation of the REM behaviour disorder phenoconversion-related pattern in an independent cohort. Neurological Sci.: Off. J. Ital. Neurological Soc. Ital. Soc. Clin. Neurophysiol. 44, 3161\u20133168 (2023).","journal-title":"Neurological Sci.: Off. J. Ital. Neurological Soc. Ital. Soc. Clin. Neurophysiol."},{"key":"49949_CR31","first-page":"221","volume":"45","author":"M Yoshida","year":"1996","unstructured":"Yoshida, M., Matsubara, S. & Tada, A. Decreased accumulation of 123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson\u2019s disease. Shinkei Naika 45, 221\u2013225 (1996).","journal-title":"Shinkei Naika"},{"key":"49949_CR32","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/jnnp.67.2.189","volume":"67","author":"S Orimo","year":"1999","unstructured":"Orimo, S., Ozawa, E., Nakade, S., Sugimoto, T. & Mizusawa, H. 123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson\u2019s disease. J. Neurol. Neurosurg. Psych. 67, 189\u2013194 (1999).","journal-title":"J. Neurol. Neurosurg. Psych."},{"key":"49949_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10286-011-0135-5","volume":"22","author":"G Treglia","year":"2012","unstructured":"Treglia, G. et al. MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. Clin. Auton. Res. J. Clin. Auton. Res. Soc. 22, 43\u201355 (2012).","journal-title":"Clin. Auton. Res. J. Clin. Auton. Res. Soc."},{"key":"49949_CR34","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.3390\/life13081786","volume":"13","author":"MS De Feo","year":"2023","unstructured":"De Feo, M. S. et al. Role of Functional Neuroimaging with 123I-MIBG and 123I-FP-CIT in De Novo Parkinson\u2019s Disease: A Multicenter Study. Life 13, 1786 (2023).","journal-title":"Life"},{"key":"49949_CR35","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"49949_CR36","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith, I. G. et al. Diagnosis and management of dementia with Lewy bodies. Neurology 89, 88\u2013100 (2017).","journal-title":"Neurology"},{"key":"49949_CR37","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jns.2004.02.018","volume":"220","author":"S Saiki","year":"2004","unstructured":"Saiki, S. et al. Cardiac 123I-MIBG scintigraphy can assess the disease severity and phenotype of PD. J. Neurol. Sci. 220, 105\u2013111 (2004).","journal-title":"J. Neurol. Sci."},{"key":"49949_CR38","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1093\/brain\/awaa238","volume":"143","author":"J Horsager","year":"2020","unstructured":"Horsager, J. et al. Brain-first versus body-first Parkinson\u2019s disease: a multimodal imaging case-control study. Brain J. Neurol. 143, 3077\u20133088 (2020).","journal-title":"Brain J. Neurol."},{"key":"49949_CR39","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ana.21995","volume":"67","author":"HC Cheng","year":"2010","unstructured":"Cheng, H. C., Ulane, C. M. & Burke, R. E. Clinical progression in Parkinson disease and the neurobiology of axons. Ann. Neurol. 67, 715\u2013725 (2010).","journal-title":"Ann. Neurol."},{"key":"49949_CR40","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.pneurobio.2015.09.012","volume":"155","author":"FA Zucca","year":"2017","unstructured":"Zucca, F. A. et al. Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson\u2019s disease. Prog. Neurobiol. 155, 96\u2013119 (2017).","journal-title":"Prog. Neurobiol."},{"key":"49949_CR41","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1002\/mrm.26584","volume":"78","author":"P Trujillo","year":"2017","unstructured":"Trujillo, P. et al. Contrast mechanisms associated with neuromelanin-MRI. Magn. Reson. Med. 78, 1790\u20131800 (2017).","journal-title":"Magn. Reson. Med."},{"key":"49949_CR42","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/jmri.28414","volume":"57","author":"N He","year":"2023","unstructured":"He, N., Chen, Y., LeWitt, P. A., Yan, F. & Haacke, E. M. Application of neuromelanin MR imaging in Parkinson disease. J. Magn. Reson. Imaging.: JMRI 57, 337\u2013352 (2023).","journal-title":"J. Magn. Reson. Imaging.: JMRI"},{"key":"49949_CR43","doi-asserted-by":"publisher","first-page":"e0282684","DOI":"10.1371\/journal.pone.0282684","volume":"18","author":"KS Hwang","year":"2023","unstructured":"Hwang, K. S., Langley, J., Tripathi, R., Hu, X. P. & Huddleston, D. E. In vivo detection of substantia nigra and locus coeruleus volume loss in Parkinson\u2019s disease using neuromelanin-sensitive MRI: Replication in two cohorts. PLoS One 18, e0282684 (2023).","journal-title":"PLoS One"},{"key":"49949_CR44","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/mds.28934","volume":"37","author":"Y Xing","year":"2022","unstructured":"Xing, Y. et al. Neuromelanin-MRI to quantify and track nigral depigmentation in Parkinson\u2019s disease: A multicenter longitudinal study using template-based standardized analysis. Mov. Disord. 37, 1028\u20131039 (2022).","journal-title":"Mov. Disord."},{"key":"49949_CR45","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1093\/brain\/awab191","volume":"144","author":"E Biondetti","year":"2021","unstructured":"Biondetti, E. et al. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson\u2019s disease. Brain: a J. Neurol. 144, 3114\u20133125 (2021).","journal-title":"Brain: a J. Neurol."},{"key":"49949_CR46","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/mds.28933","volume":"37","author":"R Gaurav","year":"2022","unstructured":"Gaurav, R. et al. Deep learning-based neuromelanin MRI changes of isolated REM sleep behavior disorder. Mov. Disord.: Off. J. Mov. Disord. Soc. 37, 1064\u20131069 (2022).","journal-title":"Mov. Disord.: Off. J. Mov. Disord. Soc."},{"key":"49949_CR47","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S1474-4422(18)30162-5","volume":"17","author":"K Knudsen","year":"2018","unstructured":"Knudsen, K. et al. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. Lancet Neurol. 17, 618\u2013628 (2018).","journal-title":"Lancet Neurol."},{"key":"49949_CR48","doi-asserted-by":"crossref","unstructured":"Pyatigorskaya, N. et al. Magnetic Resonance Imaging Biomarkers to Assess Substantia Nigra Damage in Idiopathic Rapid Eye Movement Sleep Behavior Disorder. Sleep 40, zsx149 (2017).","DOI":"10.1093\/sleep\/zsx149"},{"key":"49949_CR49","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.2169\/internalmedicine.50.5101","volume":"50","author":"K Kashihara","year":"2011","unstructured":"Kashihara, K., Shinya, T. & Higaki, F. Reduction of neuromelanin-positive nigral volume in patients with MSA, PSP and CBD. Intern. Med. 50, 1683\u20131687 (2011).","journal-title":"Intern. Med."},{"key":"49949_CR50","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.parkreldis.2014.04.005","volume":"20","author":"C Ohtsuka","year":"2014","unstructured":"Ohtsuka, C. et al. Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging. Parkinsonism Relat. Disord. 20, 755\u2013760 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"key":"49949_CR51","doi-asserted-by":"publisher","first-page":"17365","DOI":"10.1523\/JNEUROSCI.2904-12.2012","volume":"32","author":"O Pasternak","year":"2012","unstructured":"Pasternak, O. et al. Excessive extracellular volume reveals a neurodegenerative pattern in schizophrenia onset. J. Neurosci. 32, 17365\u2013U792 (2012).","journal-title":"J. Neurosci."},{"key":"49949_CR52","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1093\/brain\/awv136","volume":"138","author":"E Ofori","year":"2015","unstructured":"Ofori, E. et al. Longitudinal changes in free-water within the substantia nigra of Parkinson\u2019s disease. Brain: a J. Neurol. 138, 2322\u20132331 (2015).","journal-title":"Brain: a J. Neurol."},{"key":"49949_CR53","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/mds.29366","volume":"38","author":"G Zhou","year":"2023","unstructured":"Zhou, G. et al. Monitoring substantia nigra degeneration using free water imaging across prodromal and clinical Parkinson\u2019s disease. Mov. Disord. 38, 774\u2013782 (2023).","journal-title":"Mov. Disord."},{"key":"49949_CR54","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/brain\/awv361","volume":"139","author":"PJ Planetta","year":"2016","unstructured":"Planetta, P. J. et al. Free-water imaging in Parkinson\u2019s disease and atypical parkinsonism. Brain: a J. Neurol. 139, 495\u2013508 (2016).","journal-title":"Brain: a J. Neurol."},{"key":"49949_CR55","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1093\/brain\/awab039","volume":"144","author":"L Zhou","year":"2021","unstructured":"Zhou, L. et al. Increased free water in the substantia nigra in idiopathic REM sleep behaviour disorder. Brain: a J. Neurol. 144, 1488\u20131497 (2021).","journal-title":"Brain: a J. Neurol."},{"key":"49949_CR56","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1016\/j.neuroimage.2012.05.049","volume":"62","author":"C Langkammer","year":"2012","unstructured":"Langkammer, C. et al. Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study. NeuroImage 62, 1593\u20131599 (2012).","journal-title":"NeuroImage"},{"key":"49949_CR57","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41419-020-2298-2","volume":"11","author":"J Li","year":"2020","unstructured":"Li, J. et al. Ferroptosis: past, present and future. Cell Death Dis. 11, 88\u201388 (2020).","journal-title":"Cell Death Dis."},{"key":"49949_CR58","doi-asserted-by":"publisher","first-page":"6048","DOI":"10.1523\/JNEUROSCI.20-16-06048.2000","volume":"20","author":"N Ostrerova-Golts","year":"2000","unstructured":"Ostrerova-Golts, N. et al. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. 20, 6048\u20136054 (2000).","journal-title":"J. Neurosci."},{"key":"49949_CR59","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.mri.2015.02.021","volume":"33","author":"JHO Barbosa","year":"2015","unstructured":"Barbosa, J. H. O. et al. Quantifying brain iron deposition in patients with Parkinson\u2019s disease using quantitative susceptibility mapping, R2 and R2*. Magn. Reson. Imaging 33, 559\u2013565 (2015).","journal-title":"Magn. Reson. Imaging"},{"key":"49949_CR60","doi-asserted-by":"crossref","unstructured":"Langkammer, C. et al. Quantitative susceptibility mapping in Parkinson\u2019s disease. PLoS ONE 11, e0162460 (2016).","DOI":"10.1371\/journal.pone.0162460"},{"key":"49949_CR61","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/brain\/aww278","volume":"140","author":"J Acosta-Cabronero","year":"2017","unstructured":"Acosta-Cabronero, J. et al. The whole-brain pattern of magnetic susceptibility perturbations in Parkinson\u2019s disease. Brain: a J. Neurol. 140, 118\u2013131 (2017).","journal-title":"Brain: a J. Neurol."},{"key":"49949_CR62","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1136\/jnnp-2019-322042","volume":"91","author":"GEC Thomas","year":"2020","unstructured":"Thomas, G. E. C. et al. Brain iron deposition is linked with cognitive severity in Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 91, 418\u2013425 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"49949_CR63","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3174\/ajnr.A4260","volume":"36","author":"Y Murakami","year":"2015","unstructured":"Murakami, Y. et al. Usefulness of Quantitative Susceptibility Mapping for the Diagnosis of Parkinson Disease. AJNR Am. J. Neuroradiol. 36, 1102\u20131108 (2015).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"49949_CR64","doi-asserted-by":"publisher","first-page":"782","DOI":"10.3174\/ajnr.A4645","volume":"37","author":"M Azuma","year":"2016","unstructured":"Azuma, M. et al. Lateral Asymmetry and Spatial Difference of Iron Deposition in the Substantia Nigra of Patients with Parkinson Disease Measured with Quantitative Susceptibility Mapping. AJNR Am. J. Neuroradiol. 37, 782\u2013788 (2016).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"49949_CR65","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3988\/jcn.2018.14.1.90","volume":"14","author":"EY Kim","year":"2018","unstructured":"Kim, E. Y. et al. Diagnosis of Early-Stage Idiopathic Parkinson\u2019s Disease Using High-Resolution Quantitative Susceptibility Mapping Combined with Histogram Analysis in the Substantia Nigra at 3 T. J. Clin. Neurol. Seoul. Korea 14, 90\u201397 (2018).","journal-title":"J. Clin. Neurol. Seoul. Korea"},{"key":"49949_CR66","doi-asserted-by":"publisher","first-page":"102070","DOI":"10.1016\/j.nicl.2019.102070","volume":"24","author":"B Xiao","year":"2019","unstructured":"Xiao, B. et al. Quantitative susceptibility mapping based hybrid feature extraction for diagnosis of Parkinson\u2019s disease. NeuroImage Clin. 24, 102070 (2019).","journal-title":"NeuroImage Clin."},{"key":"49949_CR67","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ejro.2019.04.005","volume":"6","author":"V Shahmaei","year":"2019","unstructured":"Shahmaei, V., Faeghi, F., Mohammdbeigi, A., Hashemi, H. & Ashrafi, F. Evaluation of iron deposition in brain basal ganglia of patients with Parkinson\u2019s disease using quantitative susceptibility mapping. Eur. J. Radiol. Open 6, 169\u2013174 (2019).","journal-title":"Eur. J. Radiol. Open"},{"key":"49949_CR68","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.neuroimage.2018.12.041","volume":"188","author":"G Li","year":"2019","unstructured":"Li, G. et al. 3D texture analyses within the substantia nigra of Parkinson\u2019s disease patients on quantitative susceptibility maps and R2\u2217 maps. NeuroImage 188, 465\u2013472 (2019).","journal-title":"NeuroImage"},{"key":"49949_CR69","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/mds.27929","volume":"35","author":"J Sun","year":"2020","unstructured":"Sun, J. et al. Quantitative Evaluation of Iron Content in Idiopathic Rapid Eye Movement Sleep Behavior Disorder. Mov. Disord. 35, 478\u2013485 (2020).","journal-title":"Mov. Disord."},{"key":"49949_CR70","doi-asserted-by":"publisher","first-page":"117810","DOI":"10.1016\/j.neuroimage.2021.117810","volume":"230","author":"N He","year":"2021","unstructured":"He, N. et al. Imaging iron and neuromelanin simultaneously using a single 3D gradient echo magnetization transfer sequence: Combining neuromelanin, iron and the nigrosome-1 sign as complementary imaging biomarkers in early stage Parkinson\u2019s disease. NeuroImage 230, 117810 (2021).","journal-title":"NeuroImage"},{"key":"49949_CR71","doi-asserted-by":"publisher","first-page":"760975","DOI":"10.3389\/fnins.2021.760975","volume":"15","author":"B Xiao","year":"2021","unstructured":"Xiao, B. et al. Stability of AI-Enabled Diagnosis of Parkinson\u2019s Disease: A Study Targeting Substantia Nigra in Quantitative Susceptibility Mapping Imaging. Front. Neurosci. 15, 760975 (2021).","journal-title":"Front. Neurosci."},{"key":"49949_CR72","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.3233\/JPD-223499","volume":"12","author":"D Zhang","year":"2022","unstructured":"Zhang, D. et al. Quantitative susceptibility mapping and free water imaging of substantia nigra in parkinson\u2019s disease. J. Parkinson\u2019s Dis. 12, 2469\u20132478 (2022).","journal-title":"J. Parkinson\u2019s Dis."},{"key":"49949_CR73","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.acra.2020.10.027","volume":"29","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Histogram Analysis of Quantitative Susceptibility Mapping for the Diagnosis of Parkinson\u2019s Disease. Acad. Radiol. 29, S71\u2013S79 (2022).","journal-title":"Acad. Radiol."},{"key":"49949_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2022.119454","volume":"260","author":"M Lancione","year":"2022","unstructured":"Lancione, M. et al. Evaluation of iron overload in nigrosome 1 via quantitative susceptibility mapping as a progression biomarker in prodromal stages of synucleinopathies. Neuroimage 260, 119454 (2022).","journal-title":"Neuroimage"},{"key":"49949_CR75","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1021\/acschemneuro.2c00321","volume":"13","author":"Y Rong","year":"2022","unstructured":"Rong, Y. et al. Combination of Quantitative Susceptibility Mapping and Diffusion Kurtosis Imaging Provides Potential Biomarkers for Early-Stage Parkinson\u2019s Disease. ACS Chem. Neurosci. 13, 2699\u20132708 (2022).","journal-title":"ACS Chem. Neurosci."},{"key":"49949_CR76","doi-asserted-by":"publisher","first-page":"4383","DOI":"10.1021\/acschemneuro.3c00717","volume":"14","author":"D Shukla","year":"2023","unstructured":"Shukla, D. et al. Glutathione Depletion and Concomitant Elevation of Susceptibility in Patients with Parkinson\u2019s Disease: State-of-the-Art MR Spectroscopy and Neuropsychological Study. ACS Chem. Neurosci. 14, 4383\u20134394 (2023).","journal-title":"ACS Chem. Neurosci."},{"key":"49949_CR77","doi-asserted-by":"publisher","first-page":"103577","DOI":"10.1016\/j.nicl.2024.103577","volume":"41","author":"E Alushaj","year":"2024","unstructured":"Alushaj, E. et al. Increased iron in the substantia nigra pars compacta identifies patients with early Parkinson\u2019sdisease: A 3T and 7T MRI study. NeuroImage Clin. 41, 103577 (2024).","journal-title":"NeuroImage Clin."},{"key":"49949_CR78","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/mds.27549","volume":"34","author":"N Homayoon","year":"2019","unstructured":"Homayoon, N. et al. Nigral iron deposition in common tremor disorders. Mov. Disord. 34, 129\u2013132 (2019).","journal-title":"Mov. Disord."},{"key":"49949_CR79","doi-asserted-by":"publisher","first-page":"6503516","DOI":"10.21037\/qims-23-87","volume":"13","author":"Q Cao","year":"2023","unstructured":"Cao, Q. et al. Diagnostic value of combined magnetic resonance imaging techniques in the evaluation of Parkinson disease. Quant. Imaging Med. Surg. 13, 6503516\u20136506516 (2023).","journal-title":"Quant. Imaging Med. Surg."},{"key":"49949_CR80","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3389\/fneur.2020.00366","volume":"11","author":"N Pyatigorskaya","year":"2020","unstructured":"Pyatigorskaya, N. et al. Iron Imaging as a Diagnostic Tool for Parkinson\u2019s Disease: A Systematic Review and Meta-Analysis. Front. Neurol. 11, 366 (2020).","journal-title":"Front. Neurol."},{"key":"49949_CR81","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.1002\/hbm.26399","volume":"44","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. An automatic interpretable deep learning pipeline for accurate Parkinson\u2019s disease diagnosis using quantitative susceptibility mapping and T1-weighted images. Hum. Brain Mapp. 44, 4426\u20134438 (2023).","journal-title":"Hum. Brain Mapp."},{"key":"49949_CR82","doi-asserted-by":"publisher","first-page":"1287917","DOI":"10.3389\/fnagi.2023.1287917","volume":"15","author":"S Hartono","year":"2023","unstructured":"Hartono, S. et al. Quantitative iron-neuromelanin MRI associates with motor severity in Parkinson\u2019s disease and matches radiological disease classification. Front. Aging Neurosci. 15, 1287917 (2023).","journal-title":"Front. Aging Neurosci."},{"key":"49949_CR83","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.parkreldis.2021.03.004","volume":"85","author":"DH Shin","year":"2021","unstructured":"Shin, D. H. et al. Automated assessment of the substantia nigra on susceptibility map-weighted imaging using deep convolutional neural networks for diagnosis of Idiopathic Parkinson\u2019s disease. Parkinsonism Relat. Disord. 85, 84\u201390 (2021).","journal-title":"Parkinsonism Relat. Disord."},{"key":"49949_CR84","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41531-023-00557-2","volume":"9","author":"J Nepozitek","year":"2023","unstructured":"Nepozitek, J. et al. Magnetic susceptibility changes in the brainstem reflect REM sleep without atonia severity in isolated REM sleep behavior disorder. NPJ Parkinson\u2019s Dis. 9, 112 (2023).","journal-title":"NPJ Parkinson\u2019s Dis."},{"key":"49949_CR85","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0014-5793(01)03269-0","volume":"510","author":"L Zecca","year":"2002","unstructured":"Zecca, L. et al. The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson\u2019s disease. Febs Lett. 510, 216\u2013220 (2002).","journal-title":"Febs Lett."},{"key":"49949_CR86","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1002\/hbm.22360","volume":"35","author":"W Li","year":"2014","unstructured":"Li, W. et al. Differential developmental trajectories of magnetic susceptibility in human brain gray and white matter over the lifespan. Hum. Brain Mapp. 35, 2698\u20132713 (2014).","journal-title":"Hum. Brain Mapp."},{"key":"49949_CR87","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1016\/S1353-8020(13)70020-8","volume":"20","author":"B Mollenhauer","year":"2014","unstructured":"Mollenhauer, B. Quantification of \u03b1-synuclein in cerebrospinal fluid: How ideal is this biomarker for Parkinson\u2019s disease? Parkinsonism Relat. Disord. 20, S76\u2013S79 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"key":"49949_CR88","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/acn3.338","volume":"3","author":"G Fairfoul","year":"2016","unstructured":"Fairfoul, G. et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann. Clin. Transl. Neurol. 3, 812\u2013818 (2016).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"49949_CR89","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jamaneurol.2016.4547","volume":"74","author":"M Shahnawaz","year":"2017","unstructured":"Shahnawaz, M. et al. Development of a Biochemical Diagnosis of Parkinson Disease by Detection of \u03b1-Synuclein Misfolded Aggregates in Cerebrospinal Fluid. JAMA Neurol. 74, 163\u2013172 (2017).","journal-title":"JAMA Neurol."},{"key":"49949_CR90","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1002\/mds.28715","volume":"36","author":"L Concha\u2010Marambio","year":"2021","unstructured":"Concha\u2010Marambio, L. et al. Seed Amplification Assay to Diagnose Early Parkinson\u2019s and Predict Dopaminergic Deficit Progression. Mov. Disord. 36, 2444\u20132446 (2021).","journal-title":"Mov. Disord."},{"key":"49949_CR91","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40478-018-0508-2","volume":"6","author":"BR Groveman","year":"2018","unstructured":"Groveman, B. R. et al. Rapid and ultra-sensitive quantitation of disease-associated \u03b1-synuclein seeds in brain and cerebrospinal fluid by \u03b1Syn RT-QuIC. Acta Neuropathol. Commun. 6, 7 (2018).","journal-title":"Acta Neuropathol. Commun."},{"key":"49949_CR92","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/mds.27646","volume":"34","author":"UJ Kang","year":"2019","unstructured":"Kang, U. J. et al. Comparative study of cerebrospinal fluid \u03b1-synuclein seeding aggregation assays for diagnosis of Parkinson\u2019s disease. Mov. Disord. 34, 536\u2013544 (2019).","journal-title":"Mov. Disord."},{"key":"49949_CR93","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40478-021-01175-w","volume":"9","author":"C Bargar","year":"2021","unstructured":"Bargar, C. et al. Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson\u2019s disease and dementia with Lewy bodies. Acta Neuropathol. Commun. 9, 62 (2021).","journal-title":"Acta Neuropathol. Commun."},{"key":"49949_CR94","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","volume":"140","author":"M Rossi","year":"2020","unstructured":"Rossi, M. et al. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol. (Berl.) 140, 49\u201362 (2020).","journal-title":"Acta Neuropathol. (Berl.)"},{"key":"49949_CR95","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S1474-4422(20)30449-X","volume":"20","author":"A Iranzo","year":"2021","unstructured":"Iranzo, A. et al. Detection of \u03b1-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. Lancet Neurol. 20, 203\u2013212 (2021).","journal-title":"Lancet Neurol."},{"key":"49949_CR96","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s40478-023-01653-3","volume":"11","author":"S Br\u00e4uer","year":"2023","unstructured":"Br\u00e4uer, S. et al. Kinetic parameters of alpha-synuclein seed amplification assay correlate with cognitive impairment in patients with Lewy body disorders. Acta Neuropathol. Commun. 11, 162 (2023).","journal-title":"Acta Neuropathol. Commun."},{"key":"49949_CR97","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s40478-021-01292-6","volume":"9","author":"MJ Russo","year":"2021","unstructured":"Russo, M. J. et al. Correction to: High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson\u2019s disease. Acta Neuropathol. Commun. 9, 190 (2021).","journal-title":"Acta Neuropathol. Commun."},{"key":"49949_CR98","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf, A. et al. Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 22, 407\u2013417 (2023).","journal-title":"Lancet Neurol."},{"key":"49949_CR99","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s40478-021-01276-6","volume":"9","author":"K Brockmann","year":"2021","unstructured":"Brockmann, K. et al. Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson\u2019s disease and dementia with Lewy bodies. Acta Neuropathol. Commun. 9, 175 (2021).","journal-title":"Acta Neuropathol. Commun."},{"key":"49949_CR100","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/acn3.772","volume":"6","author":"A Garrido","year":"2019","unstructured":"Garrido, A. et al. \u03b1-synuclein RT-QuIC in cerebrospinal fluid of LRRK2-linked Parkinson\u2019s disease. Ann. Clin. Transl. Neurol. 6, 1024\u20131032 (2019).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"49949_CR101","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1002\/mds.28242","volume":"35","author":"S Manne","year":"2020","unstructured":"Manne, S. et al. Blinded RT-QuIC Analysis of \u03b1-Synuclein Biomarker in Skin Tissue From Parkinson\u2019s Disease Patients. Mov. Disord. J. Mov. Disord. Soc. 35, 2230\u20132239 (2020).","journal-title":"Mov. Disord. J. Mov. Disord. Soc."},{"key":"49949_CR102","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40035-019-0164-x","volume":"8","author":"CMG De Luca","year":"2019","unstructured":"De Luca, C. M. G. et al. Efficient RT-QuIC seeding activity for \u03b1-synuclein in olfactory mucosa samples of patients with Parkinson\u2019s disease and multiple system atrophy. Transl. Neurodegener. 8, 24 (2019).","journal-title":"Transl. Neurodegener."},{"key":"49949_CR103","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1002\/mds.28976","volume":"37","author":"M Luan","year":"2022","unstructured":"Luan, M. et al. Diagnostic Value of Salivary Real-Time Quaking-Induced Conversion in Parkinson\u2019s Disease and Multiple System Atrophy. Mov. Disord. J. Mov. Disord. Soc. 37, 1059\u20131063 (2022).","journal-title":"Mov. Disord. J. Mov. Disord. Soc."},{"key":"49949_CR104","doi-asserted-by":"publisher","first-page":"e1267","DOI":"10.1212\/WNL.0000000000010404","volume":"95","author":"LM Chahine","year":"2020","unstructured":"Chahine, L. M. et al. In vivo distribution of \u03b1-synuclein in multiple tissues and biofluids in Parkinson disease. Neurology 95, e1267\u2013e1284 (2020).","journal-title":"Neurology"},{"key":"49949_CR105","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/s41591-023-02358-9","volume":"29","author":"A Okuzumi","year":"2023","unstructured":"Okuzumi, A. et al. Propagative \u03b1-synuclein seeds as serum biomarkers for synucleinopathies. Nat. Med. 29, 1448\u20131455 (2023).","journal-title":"Nat. Med."},{"key":"49949_CR106","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/jnnp-2019-322588","volume":"91","author":"C Jiang","year":"2020","unstructured":"Jiang, C. et al. Serum neuronal exosomes predict and differentiate Parkinson\u2019s disease from atypical parkinsonism. J. Neurol. Neurosurg. Psychiatry 91, 720\u2013729 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"49949_CR107","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1002\/mds.29497","volume":"38","author":"M Xylaki","year":"2023","unstructured":"Xylaki, M. et al. Extracellular Vesicles for the Diagnosis of Parkinson\u2019s Disease: Systematic Review and Meta-Analysis. Mov. Disord. J. Mov. Disord. Soc. 38, 1585\u20131597 (2023).","journal-title":"Mov. Disord. J. Mov. Disord. Soc."},{"key":"49949_CR108","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1002\/mds.28639","volume":"36","author":"A Stuendl","year":"2021","unstructured":"Stuendl, A. et al. \u03b1-Synuclein in Plasma-Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson\u2019s Disease. Mov. Disord. J. Mov. Disord. Soc. 36, 2508\u20132518 (2021).","journal-title":"Mov. Disord. J. Mov. Disord. Soc."},{"key":"49949_CR109","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1093\/brain\/awac115","volume":"145","author":"A Kluge","year":"2022","unstructured":"Kluge, A. et al. Detection of neuron-derived pathological \u03b1-synuclein in blood. Brain J. Neurol. 145, 3058\u20133071 (2022).","journal-title":"Brain J. Neurol."},{"key":"49949_CR110","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-020-1608-8","volume":"20","author":"A Santaella","year":"2020","unstructured":"Santaella, A. et al. Inflammation biomarker discovery in Parkinson\u2019s disease and atypical parkinsonisms. BMC Neurol. 20, 26 (2020).","journal-title":"BMC Neurol."},{"key":"49949_CR111","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/mds.29257","volume":"38","author":"M Bartl","year":"2023","unstructured":"Bartl, M. et al. Blood Markers of Inflammation, Neurodegeneration, and Cardiovascular Risk in Early Parkinson\u2019s Disease. Mov. Disord. J. Mov. Disord. Soc. 38, 68\u201381 (2023).","journal-title":"Mov. Disord. J. Mov. Disord. Soc."},{"key":"49949_CR112","doi-asserted-by":"publisher","first-page":"e15004","DOI":"10.1371\/journal.pone.0015004","volume":"5","author":"L Gold","year":"2010","unstructured":"Gold, L. et al. Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery. PLOS ONE 5, e15004 (2010).","journal-title":"PLOS ONE"},{"key":"49949_CR113","doi-asserted-by":"publisher","first-page":"e1002931","DOI":"10.1371\/journal.pmed.1002931","volume":"16","author":"M Posavi","year":"2019","unstructured":"Posavi, M. et al. Characterization of Parkinson\u2019s disease using blood-based biomarkers: A multicohort proteomic analysis. PLoS Med. 16, e1002931 (2019).","journal-title":"PLoS Med."},{"key":"49949_CR114","doi-asserted-by":"publisher","first-page":"fcac343","DOI":"10.1093\/braincomms\/fcac343","volume":"5","author":"L Winchester","year":"2023","unstructured":"Winchester, L. et al. Identification of a possible proteomic biomarker in Parkinson\u2019s disease: discovery and replication in blood, brain and cerebrospinal fluid. Brain Commun. 5, fcac343 (2023).","journal-title":"Brain Commun."},{"key":"49949_CR115","doi-asserted-by":"publisher","first-page":"105997","DOI":"10.1016\/j.nbd.2023.105997","volume":"177","author":"IY Abdi","year":"2023","unstructured":"Abdi, I. Y. et al. Cross-sectional proteomic expression in Parkinson\u2019s disease-related proteins in drug-na\u00efve patients vs healthy controls with longitudinal clinical follow-up. Neurobiol. Dis. 177, 105997 (2023).","journal-title":"Neurobiol. Dis."},{"key":"49949_CR116","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/brain\/awab431","volume":"145","author":"I Poggiolini","year":"2022","unstructured":"Poggiolini, I. et al. Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. Brain 145, 584\u2013595 (2022).","journal-title":"Brain"},{"key":"49949_CR117","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-51334-x","volume":"14","author":"P Kivis\u00e4kk","year":"2024","unstructured":"Kivis\u00e4kk, P. et al. Clinical evaluation of a novel plasma pTau217 electrochemiluminescence immunoassay in Alzheimer\u2019s disease. Sci. Rep. 14, 629 (2024).","journal-title":"Sci. Rep."},{"key":"49949_CR118","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack, C. R. et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. J. Alzheimers Assoc. 14, 535\u2013562 (2018).","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"key":"49949_CR119","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1002\/mds.28706","volume":"36","author":"MA Laansma","year":"2021","unstructured":"Laansma, M. A. et al. International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson\u2019s Disease. Mov. Disord. 36, 2583\u20132594 (2021).","journal-title":"Mov. Disord."},{"key":"49949_CR120","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1002\/mds.29611","volume":"38","author":"R Kerestes","year":"2023","unstructured":"Kerestes, R. et al. Cerebellar Volume and Disease Staging in Parkinson\u2019s Disease: An ENIGMA-PD Study. Mov. Disord. 38, 2269\u20132281 (2023).","journal-title":"Mov. Disord."},{"key":"49949_CR121","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s00415-015-7929-7","volume":"263","author":"MM Lewis","year":"2016","unstructured":"Lewis, M. M. et al. The pattern of gray matter atrophy in Parkinson\u2019s disease differs in cortical and subcortical regions. J. Neurol. 263, 68\u201375 (2016).","journal-title":"J. Neurol."},{"key":"49949_CR122","doi-asserted-by":"publisher","first-page":"102374","DOI":"10.1016\/j.nicl.2020.102374","volume":"28","author":"M Filippi","year":"2020","unstructured":"Filippi, M. et al. Progressive brain atrophy and clinical evolution in Parkinson\u2019s disease. NeuroImage Clin. 28, 102374 (2020).","journal-title":"NeuroImage Clin."},{"key":"49949_CR123","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1093\/brain\/awv211","volume":"138","author":"E Mak","year":"2015","unstructured":"Mak, E. et al. Baseline and longitudinal grey matter changes in newly diagnosed Parkinson\u2019s disease: ICICLE-PD study. Brain 138, 2974\u20132986 (2015).","journal-title":"Brain"},{"key":"49949_CR124","doi-asserted-by":"publisher","unstructured":"Marques, A. et al. Volumetric changes and clinical trajectories in Parkinson\u2019s disease: a prospective multicentric study. J. Neurol. https:\/\/doi.org\/10.1007\/s00415-023-11947-0 (2023).","DOI":"10.1007\/s00415-023-11947-0"},{"key":"49949_CR125","doi-asserted-by":"publisher","first-page":"e2442","DOI":"10.1212\/WNL.0000000000207298","volume":"100","author":"S Verdi","year":"2023","unstructured":"Verdi, S. et al. Revealing Individual Neuroanatomical Heterogeneity in Alzheimer Disease Using Neuroanatomical Normative Modeling. Neurology 100, e2442\u2013e2453 (2023).","journal-title":"Neurology"},{"key":"49949_CR126","doi-asserted-by":"crossref","unstructured":"Bhome, R. et al. A neuroimaging measure to capture heterogeneous patterns of atrophy in Parkinson's disease and dementia with Lewy bodies. Neuroimage Clin. 42, 103596 (2024).","DOI":"10.1016\/j.nicl.2024.103596"},{"key":"49949_CR127","doi-asserted-by":"crossref","unstructured":"Abbasi, N. et al. Predicting severity and prognosis in Parkinson\u2019s disease from brain microstructure and connectivity. NeuroImage Clin. 25, 102111 (2020).","DOI":"10.1016\/j.nicl.2019.102111"},{"key":"49949_CR128","doi-asserted-by":"publisher","first-page":"e300","DOI":"10.1212\/WNL.0000000000207408","volume":"101","author":"L Wang","year":"2023","unstructured":"Wang, L. et al. Association of Cortical and Subcortical Microstructure With Clinical Progression and Fluid Biomarkers in Patients With Parkinson Disease. Neurology 101, e300\u2013e310 (2023).","journal-title":"Neurology"},{"key":"49949_CR129","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neuron.2011.08.033","volume":"72","author":"LA Volpicelli-Daley","year":"2011","unstructured":"Volpicelli-Daley, L. A. et al. Exogenous \u03b1-Synuclein Fibrils Induce Lewy Body Pathology Leading to Synaptic Dysfunction and Neuron Death. Neuron 72, 57\u201371 (2011).","journal-title":"Neuron"},{"key":"49949_CR130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41531-021-00272-w","volume":"8","author":"C Park","year":"2022","unstructured":"Park, C. et al. Simulating the progression of brain structural alterations in Parkinson\u2019s disease. Npj Park. Dis. 8, 1\u20138 (2022).","journal-title":"Npj Park. Dis."},{"key":"49949_CR131","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1007\/s00415-023-11607-3","volume":"270","author":"S Pietracupa","year":"2023","unstructured":"Pietracupa, S. et al. White and gray matter alterations in de novo PD patients: which matter most? J. Neurol. 270, 2734\u20132742 (2023).","journal-title":"J. Neurol."},{"key":"49949_CR132","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/mds.26312","volume":"31","author":"GW Duncan","year":"2016","unstructured":"Duncan, G. W. et al. Gray and white matter imaging: A biomarker for cognitive impairment in early Parkinson\u2019s disease? Mov. Disord. 31, 103\u2013110 (2016).","journal-title":"Mov. Disord."},{"key":"49949_CR133","doi-asserted-by":"publisher","unstructured":"Kamagata, K. et al. Gray Matter Abnormalities in Idiopathic Parkinson\u2019s Disease: Evaluation by Diffusional Kurtosis Imaging and Neurite Orientation Dispersion and Density Imaging. Hum. Brain Mapp. https:\/\/doi.org\/10.1002\/hbm.23628 (2017).","DOI":"10.1002\/hbm.23628"},{"key":"49949_CR134","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1002\/hbm.22302","volume":"35","author":"F Agosta","year":"2014","unstructured":"Agosta, F. et al. Mild cognitive impairment in Parkinson\u2019s disease is associated with a distributed pattern of brain white matter damage. Hum. Brain Mapp. 35, 1921\u20131929 (2014).","journal-title":"Hum. Brain Mapp."},{"key":"49949_CR135","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1007\/s00415-018-8873-0","volume":"265","author":"T Minett","year":"2018","unstructured":"Minett, T. et al. Longitudinal diffusion tensor imaging changes in early Parkinson\u2019s disease: ICICLE-PD study. J. Neurol. 265, 1528\u20131539 (2018).","journal-title":"J. Neurol."},{"key":"49949_CR136","doi-asserted-by":"publisher","first-page":"e0175674","DOI":"10.1371\/journal.pone.0175674","volume":"12","author":"C Caspell-Garcia","year":"2017","unstructured":"Caspell-Garcia, C. et al. Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. PLOS ONE 12, e0175674 (2017).","journal-title":"PLOS ONE"},{"key":"49949_CR137","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/mds.28864","volume":"37","author":"PG Scamarcia","year":"2022","unstructured":"Scamarcia, P. G. et al. Longitudinal White Matter Damage Evolution in Parkinson\u2019s Disease. Mov. Disord. 37, 315\u2013324 (2022).","journal-title":"Mov. Disord."},{"key":"49949_CR138","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1002\/mrm.22924","volume":"65","author":"J-D Tournier","year":"2011","unstructured":"Tournier, J.-D., Mori, S. & Leemans, A. Diffusion tensor imaging and beyond. Magn. Reson. Med. 65, 1532\u20131556 (2011).","journal-title":"Magn. Reson. Med."},{"key":"49949_CR139","doi-asserted-by":"publisher","first-page":"102098","DOI":"10.1016\/j.nicl.2019.102098","volume":"24","author":"Y-A Rau","year":"2019","unstructured":"Rau, Y.-A. et al. A longitudinal fixel-based analysis of white matter alterations in patients with Parkinson\u2019s disease. NeuroImage Clin. 24, 102098 (2019).","journal-title":"NeuroImage Clin."},{"key":"49949_CR140","doi-asserted-by":"crossref","unstructured":"Zarkali, A., McColgan, P., Leyland, L.-A., Lees, A. J. & Weil, R. S. Visual Dysfunction Predicts Cognitive Impairment and White Matter Degeneration in Parkinson\u2019s Disease. Mov. Disord. Mov Disord. 36, 1191\u20131202 (2021).","DOI":"10.1002\/mds.28477"},{"key":"49949_CR141","doi-asserted-by":"crossref","unstructured":"Zarkali, A. et al. Neuroimaging and plasma evidence of early white matter loss in Parkinson's disease with poor outcomes. Brain Commun. 6, fcae130 (2024).","DOI":"10.1093\/braincomms\/fcae130"},{"key":"49949_CR142","doi-asserted-by":"publisher","first-page":"e774","DOI":"10.1212\/WNL.0000000000008867","volume":"94","author":"VR Mishra","year":"2020","unstructured":"Mishra, V. R. et al. Unique white matter structural connectivity in early-stage drug-naive Parkinson disease. Neurology 94, e774\u2013e784 (2020).","journal-title":"Neurology"},{"key":"49949_CR143","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.parkreldis.2022.08.005","volume":"102","author":"YJ Kim","year":"2022","unstructured":"Kim, Y. J. et al. Identifying the white matter structural network of motor reserve in early Parkinson\u2019s disease. Parkinsonism Relat. Disord. 102, 108\u2013114 (2022).","journal-title":"Parkinsonism Relat. Disord."},{"key":"49949_CR144","doi-asserted-by":"publisher","first-page":"e1846","DOI":"10.1212\/WNL.0000000000200152","volume":"98","author":"SJ Chung","year":"2022","unstructured":"Chung, S. J. et al. Association Between White Matter Connectivity and Early Dementia in Patients With Parkinson Disease. Neurology 98, e1846\u2013e1856 (2022).","journal-title":"Neurology"},{"key":"49949_CR145","doi-asserted-by":"publisher","first-page":"102470","DOI":"10.1016\/j.nicl.2020.102470","volume":"28","author":"A Zarkali","year":"2020","unstructured":"Zarkali, A. et al. Dementia risk in Parkinson\u2019s disease is associated with interhemispheric connectivity loss and determined by regional gene expression. NeuroImage Clin. 28, 102470 (2020).","journal-title":"NeuroImage Clin."},{"key":"49949_CR146","first-page":"637","volume":"9","author":"A Tessitore","year":"2019","unstructured":"Tessitore, A., Cirillo, M. & De Micco, R. Functional Connectivity Signatures of Parkinson\u2019s Disease. J. Park. Dis. 9, 637\u2013652 (2019).","journal-title":"J. Park. Dis."},{"key":"49949_CR147","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1002\/mds.28468","volume":"36","author":"DM Herz","year":"2021","unstructured":"Herz, D. M., Meder, D., Camilleri, J. A., Eickhoff, S. B. & Siebner, H. R. Brain Motor Network Changes in Parkinson\u2019s Disease: Evidence from Meta-Analytic Modeling. Mov. Disord. J. Mov. Disord. Soc. 36, 1180\u20131190 (2021).","journal-title":"Mov. Disord. J. Mov. Disord. Soc."},{"key":"49949_CR148","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.71846","volume":"11","author":"M Oldehinkel","year":"2022","unstructured":"Oldehinkel, M. et al. Mapping dopaminergic projections in the human brain with resting-state fMRI. eLife 11, e71846 (2022).","journal-title":"eLife"},{"key":"49949_CR149","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/cns.12417","volume":"21","author":"HC Baggio","year":"2015","unstructured":"Baggio, H. C., Segura, B. & Junque, C. Resting-state functional brain networks in Parkinson\u2019s disease. CNS Neurosci. Ther. 21, 793\u2013801 (2015).","journal-title":"CNS Neurosci. Ther."},{"key":"49949_CR150","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1093\/brain\/awz192","volume":"142","author":"E Fiorenzato","year":"2019","unstructured":"Fiorenzato, E. et al. Dynamic functional connectivity changes associated with dementia in Parkinson\u2019s disease. Brain 142, 2860\u20132872 (2019).","journal-title":"Brain"},{"key":"49949_CR151","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.nicl.2017.12.013","volume":"17","author":"M D\u00edez-Cirarda","year":"2018","unstructured":"D\u00edez-Cirarda, M. et al. Dynamic functional connectivity in Parkinson\u2019s disease patients with mild cognitive impairment and normal cognition. NeuroImage Clin. 17, 847\u2013855 (2018).","journal-title":"NeuroImage Clin."},{"key":"49949_CR152","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-020-01622-9","volume":"4","author":"A Zarkali","year":"2021","unstructured":"Zarkali, A. et al. Organisational and neuromodulatory underpinnings of structural-functional connectivity decoupling in patients with Parkinson\u2019s disease. Commun. Biol. 4, 1\u201313 (2021).","journal-title":"Commun. Biol."},{"key":"49949_CR153","first-page":"9896","volume":"33","author":"G Rabini","year":"2023","unstructured":"Rabini, G. et al. Connectome-based fingerprint of motor impairment is stable along the course of Parkinson\u2019s disease. Cereb. Cortex N. Y. N. 1991 33, 9896\u20139907 (2023).","journal-title":"Cereb. Cortex N. Y. N. 1991"},{"key":"49949_CR154","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41583-018-0068-2","volume":"19","author":"R Cabeza","year":"2018","unstructured":"Cabeza, R. et al. Maintenance, reserve and compensation: the cognitive neuroscience of healthy ageing. Nat. Rev. Neurosci. 19, 701\u2013710 (2018).","journal-title":"Nat. Rev. Neurosci."},{"key":"49949_CR155","doi-asserted-by":"publisher","unstructured":"Johansson, M. E., Toni, I., Kessels, R. P. C., Bloem, B. R. & Helmich, R. C. Clinical severity in Parkinson\u2019s disease is determined by decline in cortical compensation. Brain awad325 https:\/\/doi.org\/10.1093\/brain\/awad325 (2023).","DOI":"10.1093\/brain\/awad325"},{"key":"49949_CR156","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/ene.15211","volume":"29","author":"Z Hijazi","year":"2022","unstructured":"Hijazi, Z., Yassi, N., O\u2019Brien, J. T. & Watson, R. The influence of cerebrovascular disease in dementia with Lewy bodies and Parkinson\u2019s disease dementia. Eur. J. Neurol. 29, 1254\u20131265 (2022).","journal-title":"Eur. J. Neurol."},{"key":"49949_CR157","doi-asserted-by":"publisher","first-page":"1203311","DOI":"10.3389\/fneur.2023.1203311","volume":"14","author":"W Zhao","year":"2023","unstructured":"Zhao, W. et al. Effects of white matter hyperintensity on cognitive function in PD patients: a meta-analysis. Front. Neurol. 14, 1203311 (2023).","journal-title":"Front. Neurol."},{"key":"49949_CR158","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/ene.15692","volume":"30","author":"DC Carvalho de Abreu","year":"2023","unstructured":"Carvalho de Abreu, D. C. et al. White matter hyperintensity burden predicts cognitive but not motor decline in Parkinson\u2019s disease: results from the Ontario Neurodegenerative Diseases Research Initiative. Eur. J. Neurol. 30, 920\u2013933 (2023).","journal-title":"Eur. J. Neurol."},{"key":"49949_CR159","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.nicl.2018.09.025","volume":"20","author":"M Dadar","year":"2018","unstructured":"Dadar, M. et al. White matter hyperintensities are linked to future cognitive decline in de novo Parkinson\u2019s disease patients. NeuroImage Clin. 20, 892\u2013900 (2018).","journal-title":"NeuroImage Clin."},{"key":"49949_CR160","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s13760-022-01918-z","volume":"123","author":"H Wan","year":"2023","unstructured":"Wan, H., Chen, H., Zhang, M., Feng, T. & Wang, Y. Cerebral microbleeds is associated with dementia in Parkinson\u2019s disease. Acta Neurol. Belg. 123, 407\u2013413 (2023).","journal-title":"Acta Neurol. Belg."},{"key":"49949_CR161","doi-asserted-by":"publisher","first-page":"e2880","DOI":"10.1002\/brb3.2880","volume":"13","author":"K Chen","year":"2022","unstructured":"Chen, K. et al. Lacunes may worsen cognition but not motor function in Parkinson\u2019s disease. Brain Behav. 13, e2880 (2022).","journal-title":"Brain Behav."},{"key":"49949_CR162","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.3892\/mmr.2012.1104","volume":"6","author":"A Chiaravalloti","year":"2012","unstructured":"Chiaravalloti, A. et al. Different patterns of cardiac sympathetic denervation in tremor-type compared to akinetic-rigid-type Parkinson\u2019s disease: Molecular imaging with 123I-MIBG. Mol. Med. Rep. 6, 1337\u20131342 (2012).","journal-title":"Mol. Med. Rep."},{"key":"49949_CR163","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1177\/0891988705284739","volume":"19","author":"H Matsui","year":"2006","unstructured":"Matsui, H. et al. Impaired Visual Acuity as a Risk Factor for Visual Hallucinations in Parkinson\u2019s Disease. J. Geriatr. Psychiatry Neurol. 19, 36\u201340 (2006).","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"49949_CR164","doi-asserted-by":"publisher","first-page":"S732","DOI":"10.1002\/mds.22499","volume":"24","author":"O Rascol","year":"2009","unstructured":"Rascol, O. & Schelosky, L. 123I-metaiodobenzylguanidine scintigraphy in Parkinson\u2019s disease and related disorders. Mov. Disord. 24, S732\u2013S741 (2009).","journal-title":"Mov. Disord."},{"key":"49949_CR165","doi-asserted-by":"publisher","first-page":"136399","DOI":"10.1016\/j.neulet.2021.136399","volume":"770","author":"DG Park","year":"2022","unstructured":"Park, D. G., Kang, J., An, Y.-S., Chang, J. & Yoon, J. H. Association of plasma \u03b1-synuclein with cardiac 123I-MIBG scintigraphy in early Parkinson\u2019s disease. Neurosci. Lett. 770, 136399 (2022).","journal-title":"Neurosci. Lett."},{"key":"49949_CR166","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.parkreldis.2020.10.016","volume":"81","author":"MP Giannoccaro","year":"2020","unstructured":"Giannoccaro, M. P. et al. Comparison of 123I-MIBG scintigraphy and phosphorylated \u03b1-synuclein skin deposits in synucleinopathies. Parkinsonism Relat. Disord. 81, 48\u201353 (2020).","journal-title":"Parkinsonism Relat. Disord."},{"key":"49949_CR167","doi-asserted-by":"publisher","unstructured":"Totsune, T. et al. Nuclear Imaging Data-Driven Classification of Parkinson\u2019s Disease. Mov. Disord. Off. J. Mov. Disord. Soc. https:\/\/doi.org\/10.1002\/mds.29582 (2023).","DOI":"10.1002\/mds.29582"},{"key":"49949_CR168","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-023-03350-z","volume":"23","author":"Q Liu","year":"2023","unstructured":"Liu, Q. et al. An investigation of neuromelanin distribution in substantia nigra and locus coeruleus in patients with Parkinson\u2019s disease using neuromelanin-sensitive MRI. BMC Neurol. 23, 301 (2023).","journal-title":"BMC Neurol."},{"key":"49949_CR169","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.neulet.2016.09.011","volume":"633","author":"K Matsuura","year":"2016","unstructured":"Matsuura, K. et al. A longitudinal study of neuromelanin-sensitive magnetic resonance imaging in Parkinson\u2019s disease. Neurosci. Lett. 633, 112\u2013117 (2016).","journal-title":"Neurosci. Lett."},{"key":"49949_CR170","doi-asserted-by":"publisher","first-page":"618435","DOI":"10.3389\/fnins.2021.618435","volume":"15","author":"P Ravanfar","year":"2021","unstructured":"Ravanfar, P. et al. Systematic review: Quantitative susceptibility mapping (QSM) of brain iron profile in neurodegenerative diseases. Front. Neurosci. 15, 618435 (2021).","journal-title":"Front. Neurosci."},{"key":"49949_CR171","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1002\/mds.28077","volume":"35","author":"Y Uchida","year":"2020","unstructured":"Uchida, Y. et al. Magnetic susceptibility associates with dopaminergic deficits and cognition in Parkinson\u2019s disease. Mov. Disord. 35, 1396\u20131405 (2020).","journal-title":"Mov. Disord."},{"key":"49949_CR172","doi-asserted-by":"crossref","unstructured":"Thomas, G. E. C., Hannaway, N., Zarkali, A., Shmueli, K. & Weil, R. S. Longitudinal Associations of Magnetic Susceptibility with Clinical Severity in Parkinson\u2019s Disease. Mov. Disord 39, 546\u2013559 (2020).","DOI":"10.1002\/mds.29702"},{"key":"49949_CR173","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/mds.27730","volume":"34","author":"N Bergsland","year":"2019","unstructured":"Bergsland, N. et al. Ventral posterior substantia nigra iron increases over 3 years in Parkinson\u2019s disease. Mov. Disord. 34, 1006\u20131013 (2019).","journal-title":"Mov. Disord."},{"key":"49949_CR174","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1002\/mds.27318","volume":"33","author":"G Du","year":"2018","unstructured":"Du, G. et al. Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson\u2019s patients. Mov. Disord.: Off. J. Mov. Disord. Soc. 33, 1423\u20131431 (2018).","journal-title":"Mov. Disord.: Off. J. Mov. Disord. Soc."},{"key":"49949_CR175","doi-asserted-by":"publisher","first-page":"18622","DOI":"10.18632\/aging.103870","volume":"12","author":"X Guan","year":"2020","unstructured":"Guan, X. et al. Asymmetrical nigral iron accumulation in Parkinson\u2019s disease with motor asymmetry: An explorative, longitudinal and test-retest study. Stress and. Aging Brain 12, 18622\u201318634 (2020).","journal-title":"Aging Brain"},{"key":"49949_CR176","doi-asserted-by":"publisher","first-page":"e57904","DOI":"10.1371\/journal.pone.0057904","volume":"8","author":"M Ulla","year":"2013","unstructured":"Ulla, M. et al. Is r2* a new MRI biomarker for the progression of Parkinson\u2019s disease? A longitudinal follow-up. PLoS ONE 8, e57904 (2013).","journal-title":"PLoS ONE"},{"key":"49949_CR177","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.parkreldis.2014.11.017","volume":"21","author":"M Wieler","year":"2015","unstructured":"Wieler, M., Gee, M. & Martin, W. R. W. Longitudinal midbrain changes in early Parkinson\u2019s disease: Iron content estimated from R2*\/MRI. Parkinsonism Relat. Disord. 21, 179\u2013183 (2015).","journal-title":"Parkinsonism Relat. Disord."},{"key":"49949_CR178","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1093\/brain\/awx146","volume":"140","author":"RG Burciu","year":"2017","unstructured":"Burciu, R. G. et al. Progression marker of Parkinson\u2019s disease: a 4-year multi-site imaging study. Brain J. Neurol. 140, 2183\u20132192 (2017).","journal-title":"Brain J. Neurol."},{"key":"49949_CR179","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1118\/1.597854","volume":"23","author":"JF Schenck","year":"1996","unstructured":"Schenck, J. F. The role of magnetic susceptibility in magnetic resonance imaging: MRI magnetic compatibility of the first and second kinds. Med. Phys. 23, 815\u2013850 (1996).","journal-title":"Med. Phys."},{"key":"49949_CR180","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2021.118584","volume":"244","author":"Z Zhao","year":"2021","unstructured":"Zhao, Z. et al. The effect of beta-amyloid and tau protein aggregations on magnetic susceptibility of anterior hippocampal laminae in Alzheimer\u2019s diseases. NeuroImage 244, 118584 (2021).","journal-title":"NeuroImage"},{"key":"49949_CR181","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/ana.25811","volume":"88","author":"DJ Irwin","year":"2020","unstructured":"Irwin, D. J. et al. Evolution of Alzheimer\u2019s Disease Cerebrospinal Fluid Biomarkers in Early Parkinson\u2019s Disease. Ann. Neurol. 88, 574\u2013587 (2020).","journal-title":"Ann. Neurol."},{"key":"49949_CR182","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(16)30328-3","volume":"16","author":"A Schrag","year":"2017","unstructured":"Schrag, A., Siddiqui, U. F., Anastasiou, Z., Weintraub, D. & Schott, J. M. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson\u2019s disease: a cohort study. Lancet Neurol. 16, 66\u201375 (2017).","journal-title":"Lancet Neurol."},{"key":"49949_CR183","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41531-021-00272-w","volume":"8","author":"L Batzu","year":"2022","unstructured":"Batzu, L. et al. Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson\u2019s disease. Npj Park. Dis. 8, 1\u20137 (2022).","journal-title":"Npj Park. Dis."},{"key":"49949_CR184","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA 324, 1\u201311 (2020).","journal-title":"JAMA"},{"key":"49949_CR185","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/mds.28056","volume":"35","author":"S Lerche","year":"2020","unstructured":"Lerche, S. et al. CSF NFL in a Longitudinally Assessed PD Cohort: Age Effects and Cognitive Trajectories. Mov. Disord. J. Mov. Disord. Soc. 35, 1138\u20131144 (2020).","journal-title":"Mov. Disord. J. Mov. Disord. Soc."},{"key":"49949_CR186","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1002\/mds.28779","volume":"36","author":"WW Aamodt","year":"2021","unstructured":"Aamodt, W. W. et al. Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease. Mov. Disord. J. Mov. Disord. Soc. 36, 2945\u20132950 (2021).","journal-title":"Mov. Disord. J. Mov. Disord. Soc."},{"key":"49949_CR187","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaneurol.2015.3037","volume":"73","author":"H Zetterberg","year":"2016","unstructured":"Zetterberg, H. et al. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. JAMA Neurol. 73, 60\u201367 (2016).","journal-title":"JAMA Neurol."},{"key":"49949_CR188","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/jnr.1242","volume":"66","author":"M Sj\u00f6gren","year":"2001","unstructured":"Sj\u00f6gren, M. et al. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J. Neurosci. Res. 66, 510\u2013516 (2001).","journal-title":"J. Neurosci. Res."},{"key":"49949_CR189","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","volume":"88","author":"O Hansson","year":"2017","unstructured":"Hansson, O. et al. Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder. Neurology 88, 930\u2013937 (2017).","journal-title":"Neurology"},{"key":"49949_CR190","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-32480-0","volume":"13","author":"P Youssef","year":"2023","unstructured":"Youssef, P. et al. Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson\u2019s disease biomarkers using multiplexed single molecule counting. Sci. Rep. 13, 5217 (2023).","journal-title":"Sci. Rep."},{"key":"49949_CR191","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41531-020-00149-4","volume":"7","author":"YE Huh","year":"2021","unstructured":"Huh, Y. E. et al. Glucosylceramide in cerebrospinal fluid of patients with GBA-associated and idiopathic Parkinson\u2019s disease enrolled in PPMI. Npj Park. Dis. 7, 1\u20137 (2021).","journal-title":"Npj Park. Dis."},{"key":"49949_CR192","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1002\/mds.27136","volume":"32","author":"L Parnetti","year":"2017","unstructured":"Parnetti, L. et al. Cerebrospinal fluid \u03b2-glucocerebrosidase activity is reduced in Parkinson\u2019s disease patients. Mov. Disord. 32, 1423\u20131431 (2017).","journal-title":"Mov. Disord."},{"key":"49949_CR193","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41531-022-00430-8","volume":"9","author":"Y Qu","year":"2023","unstructured":"Qu, Y. et al. A systematic review and meta-analysis of inflammatory biomarkers in Parkinson\u2019s disease. Npj Park. Dis. 9, 1\u201314 (2023).","journal-title":"Npj Park. Dis."},{"key":"49949_CR194","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1474-4422(17)30328-9","volume":"16","author":"JC Latourelle","year":"2017","unstructured":"Latourelle, J. C. et al. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson\u2019s disease: a longitudinal cohort study and validation. Lancet Neurol. 16, 908\u2013916 (2017).","journal-title":"Lancet Neurol."},{"key":"49949_CR195","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/mds.27492","volume":"34","author":"B Mollenhauer","year":"2019","unstructured":"Mollenhauer, B. et al. Baseline predictors for progression 4 years after Parkinson\u2019s disease diagnosis in the De Novo Parkinson Cohort (DeNoPa). Mov. Disord. J. Mov. Disord. Soc. 34, 67\u201377 (2019).","journal-title":"Mov. Disord. J. Mov. Disord. Soc."},{"key":"49949_CR196","doi-asserted-by":"publisher","first-page":"1142558","DOI":"10.3389\/fnagi.2023.1142558","volume":"15","author":"J Chen","year":"2023","unstructured":"Chen, J. et al. Predictors of cognitive impairment in newly diagnosed Parkinson\u2019s disease with normal cognition at baseline: A 5-year cohort study. Front. Aging Neurosci. 15, 1142558 (2023).","journal-title":"Front. Aging Neurosci."},{"key":"49949_CR197","doi-asserted-by":"publisher","unstructured":"Weil, R. S. et al. Visual dysfunction in Parkinson\u2019s disease. Brain J. Neurol. https:\/\/doi.org\/10.1093\/brain\/aww175 (2016).","DOI":"10.1093\/brain\/aww175"},{"key":"49949_CR198","doi-asserted-by":"publisher","unstructured":"Hamedani, A. G., Abraham, D. S., Maguire, M. G. & Willis, A. W. Visual Impairment Is More Common in Parkinson\u2019s Disease and Is a Risk Factor for Poor Health Outcomes. Mov. Disord. Off. J. Mov. Disord. Soc. https:\/\/doi.org\/10.1002\/mds.28182 (2020).","DOI":"10.1002\/mds.28182"},{"key":"49949_CR199","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41582-022-00618-9","volume":"18","author":"J-Y Lee","year":"2022","unstructured":"Lee, J.-Y. et al. Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease. Nat. Rev. Neurol. 18, 203\u2013220 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"49949_CR200","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.parkreldis.2019.04.023","volume":"64","author":"A Chrysou","year":"2019","unstructured":"Chrysou, A., Jansonius, N. M. & van Laar, T. Retinal layers in Parkinson\u2019s disease: A meta-analysis of spectral-domain optical coherence tomography studies. Parkinsonism Relat. Disord. 64, 40\u201349 (2019).","journal-title":"Parkinsonism Relat. Disord."},{"key":"49949_CR201","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/ana.25944","volume":"89","author":"A Murueta-Goyena","year":"2021","unstructured":"Murueta-Goyena, A. et al. Retinal Thickness Predicts the Risk of Cognitive Decline in Parkinson Disease. Ann. Neurol. 89, 165\u2013176 (2021).","journal-title":"Ann. Neurol."},{"key":"49949_CR202","doi-asserted-by":"publisher","unstructured":"Hannaway, N. et al. Visual dysfunction is a better predictor than retinal thickness for dementia in Parkinson\u2019s disease. J. Neurol. Neurosurg. Psych. https:\/\/doi.org\/10.1136\/jnnp-2023-331083 (2023).","DOI":"10.1136\/jnnp-2023-331083"},{"key":"49949_CR203","doi-asserted-by":"publisher","first-page":"e1581","DOI":"10.1212\/WNL.0000000000207727","volume":"101","author":"SK Wagner","year":"2023","unstructured":"Wagner, S. K. et al. Retinal Optical Coherence Tomography Features Associated With Incident and Prevalent Parkinson Disease. Neurology 101, e1581\u2013e1593 (2023).","journal-title":"Neurology"},{"key":"49949_CR204","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/brain\/awaa461","volume":"144","author":"NP Oxtoby","year":"2021","unstructured":"Oxtoby, N. P. et al. Sequence of clinical and neurodegeneration events in Parkinson\u2019s disease progression. Brain J. Neurol. 144, 975\u2013988 (2021).","journal-title":"Brain J. Neurol."},{"key":"49949_CR205","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","volume":"18","author":"L Parnetti","year":"2019","unstructured":"Parnetti, L. et al. CSF and blood biomarkers for Parkinson\u2019s disease. Lancet Neurol. 18, 573\u2013586 (2019).","journal-title":"Lancet Neurol."},{"key":"49949_CR206","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1002\/mds.26754","volume":"31","author":"NK Majbour","year":"2016","unstructured":"Majbour, N. K. et al. Longitudinal changes in CSF alpha-synuclein species reflect Parkinson\u2019s disease progression. Mov. Disord. 31, 1535\u20131542 (2016).","journal-title":"Mov. Disord."},{"key":"49949_CR207","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ejn.13056","volume":"43","author":"SM Williams","year":"2016","unstructured":"Williams, S. M., Schulz, P. & Sierks, M. R. Oligomeric \u03b1-synuclein and \u03b2-amyloid variants as potential biomarkers for Parkinson\u2019s and Alzheimer\u2019s diseases. Eur. J. Neurosci. 43, 3\u201316 (2016).","journal-title":"Eur. J. Neurosci."},{"key":"49949_CR208","first-page":"847","volume":"14","author":"S Korat","year":"2021","unstructured":"Korat, S. et al. Alpha-synuclein PET tracer development-an overview about current efforts. Pharm. (Basel, Switz.) 14, 847 (2021).","journal-title":"Pharm. (Basel, Switz.)"},{"key":"49949_CR209","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1016\/j.cell.2023.06.004","volume":"186","author":"J Xiang","year":"2023","unstructured":"Xiang, J. et al. Development of an alpha-synuclein positron emission tomography tracer for imaging synucleinopathies. Cell 186, 3350\u20133367 e19 (2023).","journal-title":"Cell"},{"key":"49949_CR210","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42305-3","volume":"14","author":"R Smith","year":"2023","unstructured":"Smith, R. et al. The alpha-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases. Nat. Commun. 14, 6750 (2023).","journal-title":"Nat. Commun."},{"key":"49949_CR211","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1136\/jnnp.2007.127878","volume":"79","author":"P Edison","year":"2008","unstructured":"Edison, P. et al. Amyloid load in Parkinson\u2019s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J. Neurol. Neurosurg. Psych.79, 1331\u20131338 (2008).","journal-title":"J. Neurol. Neurosurg. Psych."},{"key":"49949_CR212","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.parkreldis.2007.07.010","volume":"14","author":"A Johansson","year":"2008","unstructured":"Johansson, A. et al. [(11)C]-PIB imaging in patients with Parkinson\u2019s disease: preliminary results. Parkinsonism Relat. Disord. 14, 345\u2013347 (2008).","journal-title":"Parkinsonism Relat. Disord."},{"key":"49949_CR213","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40336-015-0104-4","volume":"3","author":"KA Frey","year":"2015","unstructured":"Frey, K. A. & Petrou, M. Imaging amyloidopathy in Parkinson disease and Parkinsonian dementia syndromes. Clin. Transl. imaging 3, 57\u201364 (2015).","journal-title":"Clin. Transl. imaging"},{"key":"49949_CR214","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/mds.29295","volume":"38","author":"K Baik","year":"2023","unstructured":"Baik, K. et al. Effect of amyloid on cognitive performance in Parkinson\u2019s disease and dementia with lewy bodies. Mov. Disord.: Off. J. Mov. Disord. Soc. 38, 278\u2013285 (2023).","journal-title":"Mov. Disord.: Off. J. Mov. Disord. Soc."},{"key":"49949_CR215","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s12035-019-01714-6","volume":"57","author":"C Ghadery","year":"2020","unstructured":"Ghadery, C. et al. The interaction between neuroinflammation and beta-amyloid in cognitive decline in Parkinson\u2019s disease. Mol. Neurobiol. 57, 492\u2013501 (2020).","journal-title":"Mol. Neurobiol."},{"key":"49949_CR216","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-022-00964-1","volume":"15","author":"AS Mihaescu","year":"2022","unstructured":"Mihaescu, A. S. et al. Beta amyloid deposition and cognitive decline in Parkinson\u2019s disease: a study of the PPMI cohort. Mol. Brain 15, 79 (2022).","journal-title":"Mol. Brain"},{"key":"49949_CR217","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1212\/WNL.0b013e31827b1a07","volume":"80","author":"SN Gomperts","year":"2013","unstructured":"Gomperts, S. N. et al. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 80, 85\u201391 (2013).","journal-title":"Neurology"},{"key":"49949_CR218","doi-asserted-by":"publisher","first-page":"1145939","DOI":"10.3389\/fneur.2023.1145939","volume":"14","author":"J Zhang","year":"2023","unstructured":"Zhang, J., Jin, J., Su, D., Feng, T. & Zhao, H. Tau-PET imaging in Parkinson\u2019s disease: a systematic review and meta-analysis. Front. Neurol. 14, 1145939 (2023).","journal-title":"Front. Neurol."},{"key":"49949_CR219","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2967\/jnumed.119.236224","volume":"61","author":"A Mueller","year":"2020","unstructured":"Mueller, A. et al. Tau PET imaging with (18)F-PI-2620 in patients with Alzheimer disease and healthy controls: A first-in-humans study. J. Nucl. Med.: Off. Publ., Soc. Nucl. Med. 61, 911\u2013919 (2020).","journal-title":"J. Nucl. Med.: Off. Publ., Soc. Nucl. Med."},{"key":"49949_CR220","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/jamaneurol.2016.3338","volume":"73","author":"SN Gomperts","year":"2016","unstructured":"Gomperts, S. N. et al. Tau positron emission tomographic imaging in the lewy body diseases. JAMA Neurol. 73, 1334\u20131341 (2016).","journal-title":"JAMA Neurol."},{"key":"49949_CR221","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/mds.27252","volume":"33","author":"SH Lee","year":"2018","unstructured":"Lee, S. H. et al. Distinct patterns of amyloid-dependent tau accumulation in Lewy body diseases. Mov. Disord.: Off. J. Mov. Disord. Soc. 33, 262\u2013272 (2018).","journal-title":"Mov. Disord.: Off. J. Mov. Disord. Soc."},{"key":"49949_CR222","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3233\/JAD-160698","volume":"55","author":"M Buongiorno","year":"2017","unstructured":"Buongiorno, M. et al. Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid-\u03b2 and Tau in Parkinson\u2019s Disease1. J. Alzheimers Dis. JAD 55, 1261\u20131272 (2017).","journal-title":"J. Alzheimers Dis. JAD"},{"key":"49949_CR223","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1093\/brain\/awab306","volume":"145","author":"E Lobanova","year":"2021","unstructured":"Lobanova, E. et al. Imaging protein aggregates in the serum and cerebrospinal fluid in Parkinson\u2019s disease. Brain 145, 632\u2013643 (2021).","journal-title":"Brain"},{"key":"49949_CR224","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/nm.3885","volume":"21","author":"T Bachhuber","year":"2015","unstructured":"Bachhuber, T. et al. Inhibition of amyloid-\u03b2 plaque formation by \u03b1-synuclein. Nat. Med. 21, 802 (2015).","journal-title":"Nat. Med."},{"key":"49949_CR225","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cell.2013.05.057","volume":"154","author":"JL Guo","year":"2013","unstructured":"Guo, J. L. et al. Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. Cell 154, 103\u2013117 (2013).","journal-title":"Cell"},{"key":"49949_CR226","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0197-4580(99)00063-9","volume":"20","author":"E Grober","year":"1999","unstructured":"Grober, E. et al. Memory and mental status correlates of modified Braak staging. Neurobiol. Aging 20, 573\u2013579 (1999).","journal-title":"Neurobiol. Aging"},{"key":"49949_CR227","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1159\/000464322","volume":"77","author":"K Mashima","year":"2017","unstructured":"Mashima, K. et al. Extremely low prevalence of amyloid positron emission tomography positivity in Parkinson\u2019s disease without dementia. Eur. Neurol. 77, 231\u2013237 (2017).","journal-title":"Eur. Neurol."},{"key":"49949_CR228","doi-asserted-by":"publisher","unstructured":"De Miranda, B. R., Van Houten, B. & Sanders, L. H. Toxin-Mediated Complex I Inhibition and Parkinson\u2019s Disease. in Mitochondrial Mechanisms of Degeneration and Repair in Parkinson\u2019s Disease (ed. Buhlman, L. M.) 115\u2013137 (Springer International Publishing, Cham). https:\/\/doi.org\/10.1007\/978-3-319-42139-1_6 (2016).","DOI":"10.1007\/978-3-319-42139-1_6"},{"key":"49949_CR229","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/toxsci\/kfx086","volume":"158","author":"LH Sanders","year":"2017","unstructured":"Sanders, L. H. et al. Editor\u2019s Highlight: Base Excision Repair Variants and Pesticide Exposure Increase Parkinson\u2019s Disease Risk. Toxicol. Sci. 158, 188\u2013198 (2017).","journal-title":"Toxicol. Sci."},{"key":"49949_CR230","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.nbd.2014.06.014","volume":"70","author":"LH Sanders","year":"2014","unstructured":"Sanders, L. H. et al. Mitochondrial DNA damage: Molecular marker of vulnerable nigral neurons in Parkinson\u2019s disease. Neurobiol. Dis. 70, 214\u2013223 (2014).","journal-title":"Neurobiol. Dis."},{"key":"49949_CR231","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40035-020-00218-x","volume":"9","author":"CU von Linstow","year":"2020","unstructured":"von Linstow, C. U., Gan-Or, Z. & Brundin, P. Precision medicine in Parkinson\u2019s disease patients with LRRK2 and GBA risk variants - Let\u2019s get even more personal. Transl. Neurodegener. 9, 39 (2020).","journal-title":"Transl. Neurodegener."},{"key":"49949_CR232","doi-asserted-by":"publisher","first-page":"eabo1557","DOI":"10.1126\/scitranslmed.abo1557","volume":"15","author":"R Qi","year":"2023","unstructured":"Qi, R. et al. A blood-based marker of mitochondrial DNA damage in Parkinson\u2019s disease. Sci. Transl. Med. 15, eabo1557 (2023).","journal-title":"Sci. Transl. Med."},{"key":"49949_CR233","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/bs.irn.2018.08.009","volume":"141","author":"AA Roussakis","year":"2018","unstructured":"Roussakis, A. A. & Piccini, P. Molecular imaging of neuroinflammation in idiopathic Parkinson\u2019s disease. Int. Rev. Neurobiol. 141, 347\u2013363 (2018).","journal-title":"Int. Rev. Neurobiol."},{"key":"49949_CR234","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/npp.2012.255","volume":"38","author":"P Edison","year":"2013","unstructured":"Edison, P. et al. Microglia, amyloid, and glucose metabolism in Parkinson\u2019s disease with and without dementia. Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 38, 938\u2013949 (2013).","journal-title":"Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"49949_CR235","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.parkreldis.2012.07.002","volume":"19","author":"S Iannaccone","year":"2013","unstructured":"Iannaccone, S. et al. In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson\u2019s disease. Parkinsonism Relat. Disord. 19, 47\u201352 (2013).","journal-title":"Parkinsonism Relat. Disord."},{"key":"49949_CR236","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1002\/acn3.50877","volume":"6","author":"N Nicastro","year":"2019","unstructured":"Nicastro, N., Surendranathan, A., Mak, E., Rowe, J. B. & O\u2019Brien, J. T. (11) C-PK11195 PET imaging and white matter changes in Parkinson\u2019s disease dementia. Ann. Clin. Transl. Neurol. 6, 2133\u20132136 (2019).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"49949_CR237","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s11481-014-9540-6","volume":"9","author":"K-R Bae","year":"2014","unstructured":"Bae, K.-R., Shim, H.-J., Balu, D., Kim, S. R. & Yu, S.-W. Translocator protein 18 kDa negatively regulates inflammation in microglia. J. NeuroImmune Pharmacol. J. Soc. NeuroImmune Pharmacol. 9, 424\u2013437 (2014).","journal-title":"J. NeuroImmune Pharmacol. J. Soc. NeuroImmune Pharmacol."},{"key":"49949_CR238","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40937-z","volume":"14","author":"E Nutma","year":"2023","unstructured":"Nutma, E. et al. Translocator protein is a marker of activated microglia in rodent models but not human neurodegenerative diseases. Nat. Commun. 14, 5247 (2023).","journal-title":"Nat. Commun."},{"key":"49949_CR239","doi-asserted-by":"publisher","unstructured":"Tan, J. B. et al. Abnormal higher-order network interactions in Parkinson\u2019s disease visual hallucinations. Brain awad305 https:\/\/doi.org\/10.1093\/brain\/awad305 (2023).","DOI":"10.1093\/brain\/awad305"},{"key":"49949_CR240","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1016\/j.celrep.2019.08.008","volume":"28","author":"J Stiso","year":"2019","unstructured":"Stiso, J. et al. White Matter Network Architecture Guides Direct Electrical Stimulation through Optimal State Transitions. Cell Rep. 28, 2554\u20132566.e7 (2019).","journal-title":"Cell Rep."},{"key":"49949_CR241","doi-asserted-by":"publisher","first-page":"ENEURO.0382","DOI":"10.1523\/ENEURO.0382-20.2021","volume":"8","author":"JD Medaglia","year":"2021","unstructured":"Medaglia, J. D. et al. Language Tasks and the Network Control Role of the Left Inferior Frontal Gyrus. eNeuro 8, ENEURO.0382\u201320.2021 (2021).","journal-title":"eNeuro"},{"key":"49949_CR242","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1093\/brain\/awaa270","volume":"143","author":"A Zarkali","year":"2020","unstructured":"Zarkali, A. et al. Differences in network controllability and regional gene expression underlie hallucinations in Parkinson\u2019s disease. Brain 143, 3435\u20133448 (2020).","journal-title":"Brain"},{"key":"49949_CR243","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2023.119862","volume":"268","author":"C Neudorfer","year":"2023","unstructured":"Neudorfer, C. et al. Lead-DBS v3.0: Mapping deep brain stimulation effects to local anatomy and global networks. NeuroImage 268, 119862 (2023).","journal-title":"NeuroImage"},{"key":"49949_CR244","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1038\/s41591-023-02296-6","volume":"29","author":"YE Tian","year":"2023","unstructured":"Tian, Y. E. et al. Heterogeneous aging across multiple organ systems and prediction of chronic disease and mortality. Nat. Med. 29, 1221\u20131231 (2023).","journal-title":"Nat. Med."},{"key":"49949_CR245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41531-020-00149-4","volume":"7","author":"S Romano","year":"2021","unstructured":"Romano, S. et al. Meta-analysis of the Parkinson\u2019s disease gut microbiome suggests alterations linked to intestinal inflammation. Npj Park. Dis. 7, 1\u201313 (2021).","journal-title":"Npj Park. Dis."},{"key":"49949_CR246","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.3390\/biomedicines10092057","volume":"10","author":"JM Nowak","year":"2022","unstructured":"Nowak, J. M., Kopczy\u0144ski, M., Friedman, A., Koziorowski, D. & Figura, M. Microbiota Dysbiosis in Parkinson Disease\u2014In Search of a Biomarker. Biomedicines 10, 2057 (2022).","journal-title":"Biomedicines"},{"key":"49949_CR247","doi-asserted-by":"publisher","first-page":"eabm1971","DOI":"10.1126\/sciadv.abm1971","volume":"8","author":"E Drori","year":"2022","unstructured":"Drori, E., Berman, S. & Mezer, A. A. Mapping microstructural gradients of the human striatum in normal aging and Parkinson\u2019s disease. Sci. Adv. 8, eabm1971 (2022).","journal-title":"Sci. Adv."},{"key":"49949_CR248","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40999-z","volume":"14","author":"S Filo","year":"2023","unstructured":"Filo, S. et al. Non-invasive assessment of normal and impaired iron homeostasis in the brain. Nat. Commun. 14, 5467 (2023).","journal-title":"Nat. Commun."},{"key":"49949_CR249","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/mrm.28685","volume":"86","author":"C Lesbats","year":"2021","unstructured":"Lesbats, C. et al. High-frequency electrical properties tomography at 9.4T as a novel contrast mechanism for brain tumors. Magn. Reson. Med. 86, 382\u2013392 (2021).","journal-title":"Magn. Reson. Med."},{"key":"49949_CR250","doi-asserted-by":"publisher","first-page":"872878","DOI":"10.3389\/fneur.2022.872878","volume":"13","author":"S Park","year":"2022","unstructured":"Park, S. et al. Application of High-Frequency Conductivity Map Using MRI to Evaluate It in the Brain of Alzheimer\u2019s Disease Patients. Front. Neurol. 13, 872878 (2022).","journal-title":"Front. Neurol."},{"key":"49949_CR251","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00401-010-0711-0","volume":"120","author":"WJ Schulz-Schaeffer","year":"2010","unstructured":"Schulz-Schaeffer, W. J. The synaptic pathology of \u03b1-synuclein aggregation in dementia with Lewy bodies, Parkinson\u2019s disease and Parkinson\u2019s disease dementia. Acta Neuropathol. 120, 131\u2013143 (2010).","journal-title":"Acta Neuropathol."},{"key":"49949_CR252","doi-asserted-by":"publisher","unstructured":"Martin, S. L., Uribe, C. & Strafella, A. P. PET imaging of synaptic density in Parkinsonian disorders. Journal of neuroscience research https:\/\/doi.org\/10.1002\/jnr.25253 (2023).","DOI":"10.1002\/jnr.25253"},{"key":"49949_CR253","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3389\/fnhum.2013.00710","volume":"7","author":"A Deistung","year":"2013","unstructured":"Deistung, A. et al. High-Resolution MR Imaging of the Human Brainstem In vivo at 7 Tesla. Front. Hum. Neurosci. 7, 710 (2013).","journal-title":"Front. Hum. Neurosci."},{"key":"49949_CR254","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.neuroimage.2016.09.023","volume":"168","author":"BR Plantinga","year":"2018","unstructured":"Plantinga, B. R. et al. Individualized parcellation of the subthalamic nucleus in patients with Parkinson\u2019s disease with 7T MRI. NeuroImage 168, 403\u2013411 (2018).","journal-title":"NeuroImage"},{"key":"49949_CR255","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/ana.22592","volume":"71","author":"D-H Kwon","year":"2012","unstructured":"Kwon, D.-H. et al. Seven-Tesla magnetic resonance images of the substantia nigra in Parkinson disease. Ann. Neurol. 71, 267\u2013277 (2012).","journal-title":"Ann. Neurol."},{"key":"49949_CR256","first-page":"591","volume":"10","author":"KL Poston","year":"2020","unstructured":"Poston, K. L. et al. Substantia Nigra Volume Dissociates Bradykinesia and Rigidity from Tremor in Parkinson\u2019s Disease: A 7 Tesla Imaging Study. J. Park. Dis. 10, 591\u2013604 (2020).","journal-title":"J. Park. Dis."},{"key":"49949_CR257","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-65752-0","volume":"10","author":"R Patriat","year":"2020","unstructured":"Patriat, R. et al. Morphological changes in the subthalamic nucleus of people with mild-to-moderate Parkinson\u2019s disease: a 7T MRI study. Sci. Rep. 10, 8785 (2020).","journal-title":"Sci. Rep."},{"key":"49949_CR258","doi-asserted-by":"publisher","first-page":"103479","DOI":"10.1016\/j.nicl.2023.103479","volume":"39","author":"AF Wolters","year":"2023","unstructured":"Wolters, A. F. et al. Neuromelanin related ultra-high field signal intensity of the locus coeruleus differs between Parkinson\u2019s disease and controls. NeuroImage Clin. 39, 103479 (2023).","journal-title":"NeuroImage Clin."},{"key":"49949_CR259","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1002\/mds.29072","volume":"37","author":"R Ye","year":"2022","unstructured":"Ye, R. et al. Locus Coeruleus Integrity from 7\u2009T MRI Relates to Apathy and Cognition in Parkinsonian Disorders. Mov. Disord. J. Mov. Disord. Soc. 37, 1663\u20131672 (2022).","journal-title":"Mov. Disord. J. Mov. Disord. Soc."},{"key":"49949_CR260","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.neurom.2022.01.003","volume":"26","author":"V Mathiopoulou","year":"2023","unstructured":"Mathiopoulou, V. et al. Utilizing 7-Tesla Subthalamic Nucleus Connectivity in Deep Brain Stimulation for Parkinson Disease. Neuromodulation J. Int. Neuromodulation Soc. 26, 333\u2013339 (2023).","journal-title":"Neuromodulation J. Int. Neuromodulation Soc."},{"key":"49949_CR261","doi-asserted-by":"publisher","unstructured":"McColgan, P. et al. Relating quantitative 7T MRI across cortical depths to cytoarchitectonics, gene expression and connectomics: a framework for tracking neurodegenerative disease. bioRxiv 2020.02.05.935080 https:\/\/doi.org\/10.1101\/2020.02.05.935080 (2020).","DOI":"10.1101\/2020.02.05.935080"},{"key":"49949_CR262","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/brain\/awv312","volume":"139","author":"B Pasquereau","year":"2016","unstructured":"Pasquereau, B., DeLong, M. R. & Turner, R. S. Primary motor cortex of the Parkinsonian monkey: altered encoding of active movement. Brain J. Neurol. 139, 127\u2013143 (2016).","journal-title":"Brain J. Neurol."},{"key":"49949_CR263","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10334-023-01063-5","volume":"36","author":"N Boulant","year":"2023","unstructured":"Boulant, N. et al. Commissioning of the Iseult CEA 11.7 T whole-body MRI: current status, gradient\u2013magnet interaction tests and first imaging experience. Magn. Reson. Mater. Phys. Biol. Med. 36, 175\u2013189 (2023).","journal-title":"Magn. Reson. Mater. Phys. Biol. Med."},{"key":"49949_CR264","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10334-023-01081-3","volume":"36","author":"S Bates","year":"2023","unstructured":"Bates, S. et al. A vision of 14 T MR for fundamental and clinical science. Magn. Reson. Mater. Phys. Biol. Med. 36, 211\u2013225 (2023).","journal-title":"Magn. Reson. Mater. Phys. Biol. Med."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-49949-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-49949-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-49949-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T17:02:42Z","timestamp":1720198962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-49949-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,5]]},"references-count":264,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["49949"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-49949-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,5]]},"assertion":[{"value":"26 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.W. has received speaking and writing honoraria respectively from GE Healthcare and Britannia, and consultancy fees from Therakind, and is local PI for an EIP neflamapimod trial. H.Z. has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). The remaining authors report no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5661"}}